Neurimmune announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a collaboration focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases.
Under the terms of the collaboration agreement Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine™ (RTM™) technology platform. The milestone triggers a pre-agreed milestone payment to Neurimmune.
“We highly appreciate a key success in drug discovery of human-derived monoclonal antibodies with Neurimmune’s proprietary platform.”, said Hiromu Habashita, Ph.D., Corporate Officer and Executive Director, Discovery and Research of Ono. “We believe this progress will lead to the delivery of a novel and innovative treatment for patients with neurodegenerative diseases.”
“We highly value the collaborative nature of our partnership with Ono, a global pioneer of innovative medicines.”, said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “We are excited about the rapid progress within the first year of this collaboration and look forward to advance novel human-derived antibody candidates for CNS indications of high unmet medical need.”
Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales.
Neurimmune is a biopharmaceutical company dedicated to the development of human-derived therapeutic antibodies for the treatment and prevention of human diseases with a high unmet medical need. Established in 2006, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the diabetes and oncology areas.